Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 1/2005

01.01.2005 | Concise Article

Ciprofloxacin treatment failure in a patient with resistant Streptococcus pneumoniae infection following prior ciprofloxacin therapy

verfasst von: M. W. R. Pletz, L. McGee, O. Burkhardt, H. Lode, K. P. Klugman

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 1/2005

Einloggen, um Zugang zu erhalten

Abstract

Reported here is the case of a patient with underlying chronic obstructive pulmonary disease (COPD) in whom ciprofloxacin treatment of a lower respiratory tract infection failed subsequent to ciprofloxacin treatment of an exacerbation of COPD several weeks earlier. During the second course of ciprofloxacin therapy, the patient’s condition continued to deteriorate, and she was admitted to the intensive care unit. Bilateral pneumonia was diagnosed. Streptococcus pneumoniae, serotype 11A, resistant to ciprofloxacin was isolated from the sputum. Sequencing revealed a S79F mutation in parC and there was evidence of an efflux pump. The patient improved rapidly after administration of azithromycin and ampicillin/sulbactam. This report of treatment failure due to ciprofloxacin-resistant Streptococcus pneumoniae shows that fluoroquinolones should be avoided when treating patients who have recently received this class of antibiotics.
Literatur
1.
Zurück zum Zitat Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C (2003) Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37:1405–1433CrossRefPubMed Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C (2003) Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37:1405–1433CrossRefPubMed
2.
Zurück zum Zitat Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P et al (2002) Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 346:747–750CrossRefPubMed Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P et al (2002) Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 346:747–750CrossRefPubMed
3.
Zurück zum Zitat Hutchinson J (2002) Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 347:65–67; author reply 65–67CrossRef Hutchinson J (2002) Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 347:65–67; author reply 65–67CrossRef
4.
Zurück zum Zitat Kays MB, Smith DW, Wack ME, Denys GA (2002) Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy 22:395–399CrossRefPubMed Kays MB, Smith DW, Wack ME, Denys GA (2002) Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy 22:395–399CrossRefPubMed
5.
Zurück zum Zitat Gertz RE Jr, McEllistrem MC, Boxrud DJ, Li Z, Sakota V, Thompson TA et al (2003) Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction. J Clin Microbiol 41:4194–4216CrossRefPubMed Gertz RE Jr, McEllistrem MC, Boxrud DJ, Li Z, Sakota V, Thompson TA et al (2003) Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction. J Clin Microbiol 41:4194–4216CrossRefPubMed
6.
Zurück zum Zitat National Committee for Clinical Laboratory Standards (2003) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. NCCLS, Wayne, PA7 National Committee for Clinical Laboratory Standards (2003) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. NCCLS, Wayne, PA7
7.
Zurück zum Zitat Fukuda H, Hiramatsu K (1999) Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 43:410–412PubMed Fukuda H, Hiramatsu K (1999) Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 43:410–412PubMed
8.
Zurück zum Zitat Gillespie SH, Voelker LL, Ambler JE, Traini C, Dickens A (2003) Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation. Microb Drug Resist 9:17–24CrossRefPubMed Gillespie SH, Voelker LL, Ambler JE, Traini C, Dickens A (2003) Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation. Microb Drug Resist 9:17–24CrossRefPubMed
9.
Zurück zum Zitat Lim S, Bast D, McGeer A, de Azavedo J, Low DE (2003) Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg Infect Dis 9:833–837PubMed Lim S, Bast D, McGeer A, de Azavedo J, Low DE (2003) Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg Infect Dis 9:833–837PubMed
10.
Zurück zum Zitat Croisier D, Etienne M, Bergoin E, Charles PE, Lequeu C, Piroth L et al (2004) Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob Agents Chemother 48:1699–1707CrossRefPubMed Croisier D, Etienne M, Bergoin E, Charles PE, Lequeu C, Piroth L et al (2004) Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob Agents Chemother 48:1699–1707CrossRefPubMed
11.
Zurück zum Zitat Anderson KB, Tan JS, File TM Jr, DiPersio JR, Willey BM, Low DE (2003) Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 37:376–381CrossRefPubMed Anderson KB, Tan JS, File TM Jr, DiPersio JR, Willey BM, Low DE (2003) Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 37:376–381CrossRefPubMed
Metadaten
Titel
Ciprofloxacin treatment failure in a patient with resistant Streptococcus pneumoniae infection following prior ciprofloxacin therapy
verfasst von
M. W. R. Pletz
L. McGee
O. Burkhardt
H. Lode
K. P. Klugman
Publikationsdatum
01.01.2005
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 1/2005
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-004-1254-x

Weitere Artikel der Ausgabe 1/2005

European Journal of Clinical Microbiology & Infectious Diseases 1/2005 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.